top of page
  • Songsong CaO

Anti-amyloid drug data readout drives up APOE testing

Interesting finding by Truveta. A 125% increase of APOE4 status testing rate during 09/22-01/23 period vs. 09/21-01/22, possibly due to lecanemab Ph3 data readout.

It makes me wonder whether there's increased demand for tau PET imaging since donanemab Ph3 data readout a few weeks ago, although tau PET is unlikely to be reimbursed currently, so we might not see any impact on the testing rate yet.

2 views0 comments


bottom of page